US Stock MarketDetailed Quotes
GNLX Genelux
- 2.270
- +0.080+3.65%
Close Dec 20 16:00 ET
78.40MMarket Cap-2.83P/E (TTM)
2.310High2.150Low63.00KVolume2.160Open2.190Pre Close141.14KTurnover0.24%Turnover RatioLossP/E (Static)34.54MShares16.60052wk High2.37P/B59.97MFloat Cap1.60052wk Low--Dividend TTM26.42MShs Float40.980Historical High--Div YieldTTM7.31%Amplitude1.600Historical Low2.240Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Genelux Stock Forum
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy With Olvi-Vec in Non-Small Cell Lung Cancer
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
$Healthy Choice Wellness (HCWC.US)$ 2nd day rally. Im in at 5.15.
$Kairos Pharma (KAPA.US)$ Also. Im in at 2.25.
$Knightscope (KSCP.US)$ Extremely high short interest after RS. Buying in at open with a goal of 7.75.
Plan on being in the green and up 40% at the end of the day.
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
Genelux (NASDAQ: GNLX) reported its Q2 2024 financial results and provided business updates. The company completed a $30 million public offering, providing runway through three trial readouts. Genelux anticipates interim results from the Phase 2 trial in recurrent non-small cell lung cancer by mid-2025 and interim data from the Phase 1b trial in recurrent small cell...
Larger Image: tradingview.com...
$Genelux (GNLX.US)$
In the volatile world of biotech investments, pinpointing potential high-reward stocks can be akin to finding a needle in a haystack. Yet, the recent analysis by Benchmark on Genelux Corporation (Ticker Symbol: GNLX) has caught the attention of many in the industry. With a reiterated speculative buy rating and a staggering price target of $30—nearly six times its current trading pri...
dropped from 35-20 in 7 days
missed my entry
No comment yet